Recurrent copy number alterations in prostate cancer: An in silico meta-analysis of publicly available genomic data

Cancer Genetics

Volumn 207, Issue 10-12, 2014, Pages 474-488

  Williams, Julia L ^a   Greer, Peter A ^a   Squire, Jeremy A ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Array CGH; Bioinformatics; Genomic instability; PI3 kinase; Tumor suppressor

Indexed keywords

ARTICLE; CANCER GENETICS; CHROMOSOMAL INSTABILITY; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; GENE DELETION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUSION; GENE REARRANGEMENT; GENETIC ANALYSIS; GENETIC GAIN; GENETIC LINKAGE; GLEASON SCORE; HEMIZYGOSITY; HOMOZYGOSITY; HUMAN; ONCOGENE; PROSTATE CANCER; PTEN GENE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TMPRSS2 ERG GENE; CHROMOSOME ABERRATION; CHROMOSOME MAP; GENETIC DATABASE; GENETICS; GENOMICS; HUMAN CHROMOSOME; MALE; META ANALYSIS; PATHOLOGY; PROCEDURES; PROSTATE TUMOR;

CHROMOSOME ABERRATIONS; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN; DATABASES, GENETIC; DNA COPY NUMBER VARIATIONS; GENOMICS; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84919684630     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2014.09.003     Document Type: Article

References (54)

1. Siegel R., Naishadham D., Jemal A. Cancer Statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
2. Roychowdhury S., Chinnaiyan A.M. Advancing precision medicine for prostate cancer through genomics. JClin Oncol 2013, 31:1866-1873.
3. Catalogue of Somatic Mutations in Cancer (COSMIC), 2014. http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/.
4. Sun J.J., Liu W., Adams T.S., et al. DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate 2007, 67:692-700.
5. Lapointe J., Li C., Giacomini C.P., et al. Genomic profiling reveals distinct pathways of prostate tumorigenesis with clinical implications. Cancer Res 2007, 67:8504-8510.
6. Taylor B.S., Schultz N., Hieronymus H., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11-22.
7. Barbieri C.E., Bangma C.H., Bjartell A., et al. The mutational landscape of prostate cancer. Eur Urol 2013, 64:567-576.
8. Yoshimoto M., Joshua A.M., Cunha I.W., et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol 2008, 21:1451-1460.
9. King J.C., Xu J., Wongvipat J., et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 2009, 41:524-526.
10. Carver B.S., Tran J., Gopalan A., et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009, 41:619-624.
11. Yoshimoto M., Cunha I.W., Coudry R.A., et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007, 97:678-685.
12. Attard G., Clark J., Ambroisine L., et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008, 27:253-263.
13. Visakorpi T., Hyytinen E., Koivisto P., et al. Invivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995, 9:401-406.
14. Mao X., Yu Y., Boyd L.K., et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res 2010, 70:5207-5212.
15. Boyd L.K., Mao X., Xue L., et al. High-resolution genome-wide copy-number analysis suggests a monoclonal origin of multifocal prostate cancer. Genes Chromosomes Cancer 2012, 51:579-589.
16. Demichelis F., Setlur S.R., Beroukhim R., et al. Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes Chromosomes Cancer 2009, 48:366-380.
17. Beroukhim R., Mermel C.H., Porter D., et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463:899-905.
18. Kan Z., Jaiswal B.S., Stinson J., et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010, 466:869-873.
19. Grasso C.S., Wu Y.-M., Robinson D.R., et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012, 487:239-243.
20. Castro P., Creighton C., Ozen M., et al. Genomic profiling of prostate cancers from African American men. Neoplasia 2009, 11:305-312.
21. Liu W., Laitinen S., Khan S., et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009, 15:559-565.
22. Friedlander T.W., Roy R., Tomlins S.A., et al. Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res 2012, 72:616-625.
23. Vainio P., Wolf M., Edgren H., et al. Integrative genomic, transcriptomic, and RNAi analysis indicates a potential oncogenic role for FAM110B in castration-resistant prostate cancer. Prostate 2012, 72:789-802.
24. Huang S., Gulzar Z.G., Salari K., et al. Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness. Oncogene 2012, 31:4164-4170.
25. Watson S.K., Woolcock B.W., Fee J.N., et al. Minimum altered regions in early prostate cancer progression identified by high resolution whole genome tiling path BAC array comparative hybridization. Prostate 2009, 69:961-975.
26. Ishkanian A.S., Mallof C.A., Ho J., et al. High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. Prostate 2009, 69:1091-1100.
27. Greenlee R.T., Hill-Harmon M.B., Murray T., et al. Cancer statistics, 2001. CA Cancer J Clin 2001, 51:15-36.
28. Amin M., Grignon D., Humphrey P., et al. Gleason grading of prostate cancer: a contemporary approach 2004, Lippincott Williams & Wilkins, Philadelphia.
29. Futreal P.A., Coin L., Marshall M., et al. Acensus of human cancer genes. Nat Rev Cancer 2004, 4:177-183.
30. Forbes S.A., Bindal N., Bamford S., et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011, 39:D945-D950.
31. Cai H., Kumar N., Ai N., et al. Progenetix: 12 years of oncogenomic data curation. Nucleic Acids Res 2014, 42:D1055-D1062.
32. Baudis M. Progenetix oncogenomic online resource http://www.progenetix.net.
33. Reid A.H.M., Attard G., Ambroisine L., et al. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 2010, 102:678-684.
34. Yoshimoto M., Ludkovski O., DeGrace D., et al. PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications. Genes Chromosomes Cancer 2012, 51:149-160.
35. Barbieri C.E., Tomlins S.A. The prostate cancer genome: perspectives and potential. Urol Oncol 2014, 53:e15-e22.
36. Barbieri C.E., Baca S.C., Lawrence M.S., et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012, 44:685-689.
37. Baca S.C., Prandi D., Lawrence M.S., et al. Punctuated evolution of prostate cancer genomes. Cell 2013, 153:666-677.
38. Beltran H., Yelensky R., Frampton G.M., et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol 2013, 63:920-926.
39. Lindberg J., Mills I.G., Klevebring D., et al. The mitochondrial and autosomal mutation landscapes of prostate cancer. Eur Urol 2013, 63:702-708.
40. Berger M.F., Lawrence M.S., Demichelis F., et al. The genomic complexity of primary human prostate cancer. Nature 2011, 470:214-220.
41. Barbieri C.E., Demichelis F., Rubin M.A. Molecular genetics of prostate cancer: emerging appreciation of genetic complexity. Histopathology 2012, 60:187-198.
42. Krohn A., Diedler T., Burkhardt L., et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol 2012, 181:401-412.
43. Sircar K., Yoshimoto M., Monzon F.A., et al. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. JPathol 2009, 218:505-513.
44. Williams J., Yoshimoto M., Boag A., et al. TMPRSS2:ETS gene fusions in prostate cancer. Atlas Genet Cytogenet Oncol Haematol 2010, 15:699-716.
45. Puc J., Keniry M., Li H.S., et al. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 2005, 7:193-204.
46. Shen W.H., Balajee A.S., Wang J., et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007, 128:157-170.
47. Dedes K.J., Wetterskog D., Mendes-Pereira A.M., et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med 2010, 2:53-75.
48. Chatterjee P., Choudhary G.S., Sharma A., et al. PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells. PLoS One 2013, 8:e60408.
49. Mukherjee A., Karmakar P. Attenuation of PTEN perturbs genomic stability via activation of Akt and down-regulation of Rad51 in human embryonic kidney cells. Mol Carcinog 2013, 52:611-618.
50. Fraser M., Zhao H., Luoto K.R., et al. PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clin Cancer Res 2012, 18:1015-1027.
51. Gupta A., Yang Q., Pandita R.K., et al. Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle 2009, 8:2198-2210.
52. Bismar T.A., Yoshimoto M., Vollmer R.T., et al. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer. BJU Int 2011, 107:477-485.
53. Leinonen K.A., Saramäki O.R., Furusato B. Loss of PTEN is associated with aggressive behavior in ERG-positive prostatecancer. Cancer Epidemiol Biomarkers Prev 2013, 22:2333-2344.
54. Jiang F., He H., Zhang Y., et al. An integrative proteomics and interaction network-based classifier for prostate cancer diagnosis. PLoS One 2013, 8:e63941.